From
To
GoodRx reports that once-a-week insulin, such as Awiqli, offers a convenient option for Type 2 diabetes management, simplifying injections and storage.
Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ongoing studies are needed.